(Q35213229)

7 August 2017

1 reference

title

Optimizing primary chemotherapy in ovarian cancer (English)

1 reference

7 August 2017

1 reference

1 reference

Maurie Markman

1

1 reference

7 August 2017

publication date

1 August 2003

1 reference

Hematology / Oncology Clinics of North America

7 August 2017

published in

1 reference

7 August 2017

volume

17

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

957-68, viii

1 reference

Epithelial carcinoma of the ovary: current strategies

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

1 reference

7 January 2021

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

The impact of received dose intensity on the outcome of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: A comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Impact of doxorubicin on survival in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900058-3

7 January 2021

10.1016/S0889-8588(03)00058-3

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fhzliy2bhfbndbgcx7ikwfgefm

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_fhzliy2bhfbndbgcx7ikwfgefm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fhzliy2bhfbndbgcx7ikwfgefm

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/fhzliy2bhfbndbgcx7ikwfgefm

1 reference

30 July 2022